BioSpace News Archive

Total Revenue of $12.1 Million Increased 110% Year-over-Year and 46% Sequentially First Quarter 2020 Conference Call Scheduled for May 14

FX received 510k clearances for their Humeral Cup Stability & Humeral Cup 135/145° Stability for reverse shoulder arthroplasty.

Correvio Pharma Corp. today announced that Institutional Shareholder Services Inc. (“ISS”), a leading independent proxy advisory firm, released a report (the “ISS Report”) recommending that Correvio shareholders vot

New Data For Teva AJOVY ® (fremanezumab-vfrm) Injection and AUSTEDO ® (deutetrabenazine) Tablets Included in Neurology 23 abstracts appeared in the 2020 American Academy of Neurology (AAN) Science Highlights Supplement

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2020 financial results after the U.S. financial markets close on Thursday, May 7, 2020. Oncternal’s management will host a webcast and conference call at 2:00 p.m. PDT (5:00 p.m. EDT) to discuss the Company’s financial results and provide

VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC, which holds a principal amount of approximately $170.1 million of the Company’s Convertible Senior Notes with a maturity date of May 1, 2020. The Company does not currently have the ability to pay the principal amount of the Convertible Senior Notes held by IEH Biopharma. Under the terms of

Alexion Receives CHMP Positive Opinion for ULTOMIRIS ® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced that based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic,

Convalescent plasma (i.e., the component of blood known as plasma obtained from people who have recovered from COVID-19)

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s first quarter 2020 financial results will be released on Thursday, May 7, 2020.